Almirall SA
(OTC: ALMRY)
|
2:34 PM UTC, 07/01/24 | |||
---|---|---|---|---|
Last: $10.22 | Change: +0.03 | %Change: +0.29% | Volume: 100 |
Open: | $ 10.22 | Volume: | 100 | |
---|---|---|---|---|
High: | $ 10.22 | Yield(%) | 1.19 | |
Low: | $ 10.22 | P/E Ratio (ttm): | n/a | |
Dividend ($): | 0.12 | Market Cap ($): | 2.15B | |
EPS ($) | 0.70 | Shares Out: | 213.47M |
% Price Change (last 4 weeks): | -4.07 |
---|---|
% Price Change (last 13 weeks): | 15.25 |
% Price Change (last 26 weeks): | 6.75 |
% Price Change (last 52 weeks): | 20.90 |
% Price Change (year to date): | 8.41 |
Return on Equity (%): | -2.75 |
---|---|
Return on Assets (%): | -1.69 |
Return on Invested Capital (%): | 1.16 |
Gross Profit Margin (%): | 39.01 |
---|---|
Net Profit Margin (%): | -4.30 |
Operating Profit Margin (%): | 4.46 |
|
|
50-day Moving Average: | $n/a |
---|---|
200-day Moving Average: | $n/a |
Avg. Daily Vol. (last 50 days): | n/a |
Avg. Daily Vol. (last 200 days): | n/a |
52-wk high: | $n/a |
52-wk low: | $n/a |
Bid: | $n/a |
Ask: | $n/a |
Almirall SA is a global biopharmaceutical company, which is focused on skin health. It engages in the development, manufacture, storage, commercialization and sale of pharmaceutical and cosmetic products, as well as of the raw materials used in production. The firm operates through the following segments: Marketing through Own Network, Marketing by Licensees, Research and Development Activity, Therapeutic Area of Dermatology in the United States, and Corporate Management and Results not Allocated Assigned to Other Segments. Its products include treatments for respiratory, autoimmune, dermatological, and gastrointestinal diseases. The company was founded in 1943 and is headquartered in Barcelona, Spain.
|
Almirall SA
Ronda General Mitre, 151 Barcelona CT 08022 Phone: 34.93.291.30.00 Fax: 34.93.291.31.80 http://www.almirall.com |
Earnings (1year) ($): | -0.19 |
---|---|
Annual Dividend ($): | 0.12 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 7.72 |
Cash Flow ($): | 0.44 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 1.90 |
Price/Book (x): | 1.21 |
Price/Cash Flow (x): | 19.19 |
Quick Ratio (x): | 1.57 |
---|---|
Current Ratio (x): | 2.05 |
LT Debt/Equity (x): | 25.93 |
Total Debt/Equity (x): | 27.14 |